Peptide-Drug Conjugates: The Next Evolution Beyond Antibody-Drug Conjugates for Cancer Treatment

PDCs offer several advantages over ADCs: more accessible industrial synthesis, versatile functionalization, high tissue penetration, rapid clearance, and low immunotoxicity. Three peptide categories serve different delivery functions — tumor-targeting peptides for specificity, cell-penetrating peptides for intracellular delivery, and self-assembling peptides for controlled release and nanostructure formation. PDCs can overcome drug resistance, control drug release, and improve efficacy while reducing off-target toxicity. However, poor pharmacokinetic properties and low bioactivity remain the primary clinical development challenges.

Comprehensive narrative review analyzing PDC design principles (informed by ADC success factors), component functions (peptides, linkers, payloads), peptide categories, pharmacokinetics, and current clinical trial landscape. The review draws comparisons between PDCs and established ADC technology throughout.

ADCs represent a multi-billion-dollar cancer drug market, but their large antibody size limits tissue penetration and manufacturing is complex and expensive. If PDCs can overcome their current pharmacokinetic limitations, they could democratize targeted cancer therapy — being cheaper to produce, easier to modify, and capable of reaching tumors that antibodies cannot. With several PDCs now in clinical trials, this technology is approaching real-world clinical impact.

The PDC field sits at the intersection of two major pharmaceutical trends: the explosion of targeted cancer therapies (led by ADCs) and the maturation of peptide therapeutics. ADCs like trastuzumab deruxtecan have shown transformative clinical results, but their manufacturing complexity and cost limit global access. PDCs could potentially deliver similar targeted therapy at a fraction of the cost, with the added ability to reach solid tumors that large antibodies struggle to penetrate. This review provides a roadmap for the field at a critical inflection point.

As a narrative review, this does not include systematic methodology or meta-analysis. The comparison between PDCs and ADCs is partially theoretical — very few PDCs have completed late-stage clinical trials, so the real-world performance gap remains uncertain. The challenges highlighted (pharmacokinetics, bioactivity) are significant and may limit which tumor types PDCs can effectively treat. Self-assembling peptide systems are particularly early in development.